Scandion Oncology A/S

About Us

Scandion Oncology A/S is a clinical stage II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including, chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.

Contacts

Bo Rode Hansen

President & CEO

Fruebjergvej 3 DK-2100 Copenhagen
+45 38 10 20 17
http://www.scandiononcology.com
bh@scandiononcology.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Scandion Oncology receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101

Thu, Jan 19, 2023 13:00 CET

The patent would provide protection of the commercial solid form of SCO-101 until at least 2042.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has received a favorable patentability opinion from the European Patent Office (EPO) on an international patent application aiming to further enhance the patent protection of Scandion’s lead compound SCO-101. If granted, the patent will prolong the potential commercial exclusivity period for SCO-101. This could also allow Scandion to

Scandion Oncology appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management

Wed, Jan 18, 2023 14:00 CET

Jan Stenvang is co-founder of Scandion Oncology and has more than 20 years of experience in cancer research.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, strengthens its Executive Management with the inclusion of Jan Stenvang, who is appointed Chief Scientific Officer (CSO) reporting directly to CEO Francois Martelet. A co-founder of Scandion, Jan Stenvang led the initial research and discoveries upon which Scandion is based. He has headed the company’s research and early

Scandion Oncology announces share purchase by incoming President & CEO

Mon, Dec 05, 2022 08:30 CET

Scandion Oncology, a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options today announced that the incoming President & CEO has purchased shares in the company.Incoming President & CEO Francois Martelet has reported that he has bought 11.184 shares. Persons under an obligation to report are persons discharging managerial responsibilities, as well as persons closely associated with them. For further information please contact: Johnny Stilou, Acting CEO & CFO Phone: +45 2960 3532 E-mail: jos@

Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer

Thu, Dec 01, 2022 08:30 CET

Bringing more than 20 years of experience as a senior level executive in the global pharmaceutical and biotech industry, Francois Martelet will join Scandion Oncology on January 2, 2023.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces that the company’s Board of Directors has appointed Francois Martelet as new Chief Executive Officer (CEO). Francois will take up his new position on January 2, 2023. Trained as a Medical Doctor with a Master’s degree in Business, Francois

Scandion Oncology announces share purchase by member of the Board of Directors

Wed, Nov 23, 2022 08:30 CET

Scandion Oncology, a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options today announced that a member of the Board of Directors has purchased shares in the company.Board member Nils Brünner has reported that he has bought 38.393 shares. This brings his total shareholding up to 304,944 shares. Persons under an obligation to report are persons discharging managerial responsibilities, as well as persons closely associated with them. For further information please contact: Johnny Stilou, Acting CEO & CFO Phone:

Scandion Oncology – Interim Report Q3 2022

Wed, Nov 16, 2022 08:30 CET

Scandion Oncology (Scandion) today announces its interim report for Q3 2022. The following is taken from the report. Johnny Stilou, Acting CEO & CFO, comments “In the third quarter of 2022 we managed to raise approximately 42 MDKK net in a very difficult stock market. The raised capital will take us well into 2024.” Key Figures & Highlights TDKK Q3 2022 Q1-Q3 2022 Q3 2021 Q1-Q3 2021 FY 2021 Operating -23,626 -64,778 -15,392 -40,788 -55,367loss Net finance -1,447 -1,735 -359 -1,606 -1,846income/

Invitation to Scandion Oncology webcast and conference call November 16, 2022

Thu, Nov 10, 2022 08:30 CET

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, will publish its Q3 2022 interim report on Wednesday November 16, 2022, before 09:00 CET. Scandion’s Executive Management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session.Access to the event can be obtained as follows: LIVE access on Wednesday November 16, 2022, at 10:00 CET Webcast: https://

Scandion Oncology Announces Results of Extraordinary General Meeting

Fri, Oct 28, 2022 12:15 CET

On 28 October 2022 at 11:00 a.m. an Extraordinary General Meeting was held in Scandion Oncology A/S (the "Company").All proposals were adopted in accordance with the notice. The full minutes of the extraordinary general meeting are attached to this notice. The agenda of the extraordinary general meeting was as follows: 1. Election of chairman of the meeting 2. Election of an additional member of the board of directors 3. Proposal to authorize the board of directors to issue shares with pre-emptive rights for the Company's existing shareholders 4. Proposal to

Scandion Oncology – Notice convening an Extraordinary General Meeting

Thu, Oct 13, 2022 17:30 CET

The board of directors hereby give notice of an extraordinary general meetingin: Scandion Oncology A/SCVR-no. 38613391(the "Company")Friday, October 28, 2022, at 11 am (CET), at the Company's address,Fruebjergvej 3, 2100 Copenhagen, Denmark. Agenda of the extraordinary general meeting: 1. Election of chairman of the meeting 2. Election of an additional member of the board of directors 3. Proposal to authorize the board of directors to issue shares with pre-emptive rights for the Company's existing shareholders 4. Proposal to authorize the board of

Scandion Oncology initiates part 3 of the CORIST phase II trial

Mon, Oct 10, 2022 17:00 CET

The first of up to 36 patients has been enrolled in part 3 of the CORIST trial in accordance with the planned timeline.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has as planned initiated part 3 of the CORIST phase II trial studying Scandion’s lead compound SCO-101 as a combination treatment in patients with metastatic colorectal cancer (mCRC). The first of up to 36 patients has been enrolled as the development of SCO-101 seamlessly continues with the momentum from the ongoing

Scandion Oncology announce topline results from part 2 of the CORIST phase II trial

Fri, Sep 30, 2022 10:30 CET

Data from part 2 of the trial confirm the safety and tolerability of SCO-101. The trial will continue with part 3 exploring an optimized dosing schedule, aiming to utilize the full potential of SCO-101 in this indication and combination.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announce the topline results from the second part of the ongoing CORIST phase II trial studying Scandion’s lead compound SCO-101 as a combination treatment with FOLFIRI chemotherapy in patients with

Bo Rode Hansen is leaving the position as President and CEO of Scandion Oncology

Wed, Aug 31, 2022 11:45 CET

Johnny Stilou, Chief Financial Officer at Scandion Oncology since July 2021, has been appointed acting CEO effective immediately. The process to identify a new permanent CEO has started.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces that President and CEO Bo Rode Hansen by mutual agreement will leave his position with immediate effect. Johnny Stilou, who has been employed by Scandion as Chief Financial Officer since July 2021, has been appointed acting CEO effective

Scandion Oncology announce change to its Executive Management

Tue, Aug 30, 2022 08:55 CET

Maj Hedtjärn has decided to resign from her position as Chief Operating Officer and Head of R&D Operations. She will leave Scandion Oncology no later than December 31, 2022.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces that Maj Hedtjärn, Chief Operating Officer, Head of R&D Operations and member of Executive Management, has decided to resign from her position to pursue new opportunities outside Scandion. Maj Hedtjärn will leave Scandion no later than December 31, 2022,

Scandion Oncology – Interim Report Q2 2022

Thu, Aug 25, 2022 08:30 CET

Scandion Oncology (Scandion) today announces its interim report for Q2 2022. The following is taken from the report. Bo Rode Hansen, President and CEO, comments “The second quarter of 2022 saw us raise capital to fund our operations into 2024 and maintain momentum in our clinical trials as we continue to execute on our strategy to ensure long term value creation” Key Figures & Highlights TDKK Q1 2022 Q1-Q2 2022 Q1 2021 Q1-Q2 2022 FY 2021 Operating -24,840 -41,152 -15,493 -25,397 -55,367loss Net finance -37 -

Scandion Oncology receives approvals for next parts of the CORIST trial

Fri, Aug 19, 2022 08:30 CET

The development of SCO-101 will continue as planned with expansion of the CORIST trial expected to commence during the third quarter of 2022.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has now received approvals from authorities and ethical committees in Denmark and Germany for the next parts of the ongoing CORIST phase II-trial. The trial studies Scandion’s lead compound SCO-101 as a combination treatment in patients with metastatic colorectal cancer (mCRC). Thus, the

Invitation to Scandion Oncology webcast and conference call August 25, 2022

Thu, Aug 18, 2022 17:30 CET

Scandion Oncology (Scandion) will publish its Q2 2022 interim report on Thursday, August 25, 2022 before 09:00 CET. Scandion’s Executive Management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session.Access to the event can be obtained as follows: LIVE access on Thursday August 25, 2022 at 10:00 CET https://financialhearings.com/event/43548

Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101

Wed, Aug 17, 2022 08:30 CET

Good tolerability allows for continued dose escalation in the dose-finding PANTAX phase 1b-trial with SCO-101 as combination therapy in pancreatic cancer. Consequently, readout from the trial is now expected in the first half of 2023.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has observed a better-than-expected tolerability of its potential new cancer treatment SCO-101 in the dose-finding PANTAX phase 1b-trial. Thus, dosing is now escalated to higher levels than expected based

Scandion Oncology announces share purchase by Board of Directors

Mon, Aug 08, 2022 17:30 CET

Member of the Board of Directors has purchased shares in the company.Deputy Chair, Jørgen Bardenfleth has reported that he has bought 32,000 shares, which brings his total shareholding up to 457,629 shares. Persons under an obligation to report are persons discharging managerial responsibilities, as well as persons closely associated with them. 1. Details of the person discharging managerial responsibilities/person closely associateda) Name Jørgen Bardenfleth2. Reason for the notificationa) Position/status

Scandion Oncology’s rights issue registered with the Danish Business Authority

Tue, Jul 26, 2022 17:30 CET

Share capital increase and updated articles of association have been registered with the Danish Business Authority.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant

Scandion Oncology announces final outcome of its rights issue

Mon, Jul 04, 2022 19:00 CET

Through the issue, Scandion raises approximately SEK 75 million before deduction of issue related costs.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Scandion Oncology ("Scandion" or the "Company"), a biotech company developing first-in-class medicines aimed at treating cancer which is

Scandion Oncology announces preliminary outcome of its rights issue

Fri, Jul 01, 2022 22:00 CET

The subscription period in Scandion Oncology’s (“Scandion” or the “Company”) rights issue of shares (the “Rights Issue”) ended today, July 1, 2022. The preliminary outcome of Scandion’s Rights Issue of shares of up to SEK 93.7 million indicates that shares, corresponding to approximately 80% of the Rights Issue, were subscribed for, including subscriptions by guarantors. Through the Rights Issue, Scandion raises approx. SEK 75 million before deduction of issue related costs.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA,

Subscription period in Scandion Oncology Rights Issue of up to approximately SEK 93.7 million commences

Thu, Jun 16, 2022 08:30 CET

The Rights Issue is also open for subscriptions to the public.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Scandion Oncology (Scandion or “The Company”), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options,

Scandion Oncology publishes prospectus in connection with the rights issue of up to approximately SEK 93.7 million

Wed, Jun 15, 2022 09:00 CET

The prospectus has today been approved and registered by the Danish Financial Supervisory Authority (Finanstilsynet).NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Scandion Oncology (Scandion or “The Company”), a biotech company developing first-in-class medicines aimed at treating cancer

There are no items matching the current filter

There are no more items matching the current filter

Share